Xalud Therapeutics receives FDA fast track designation for XT-150 for the treatment of pain associated with osteoarthritis of the knee

Xalud Therapeutics

17 December 2021 - Xalud Therapeutics announced today that the United States FDA has granted fast track designation to the Company’s lead candidate, XT-150, for the treatment of pain associated with osteoarthritis of the knee. 

XT-150 is a locally injectable non-viral therapy expressing IL-10v, a proprietary modified variant of IL-10, that addresses pathologic inflammation and pain.

Read Xalud Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track